Folding without glutamine: Proteome-scale removal of a canonical amino acid
PLOS Computational Biology · 03.11.2026 · 22 (11) · e1014931
DOI: 10.1371/journal.pcbi.1014931 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 03.11.2026. Verfasst von Alejandro Garciarrubio und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ingeniería Celular y Biocatálisis, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México. Hauptthemen laut MEDLINE: Proteome, Glutamine, Protein Folding, Amino Acids. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secihti,Mexico.
Abstract (Originalsprache)
All known life uses a canonical alphabet of 20 amino acids, yet which residues are structurally essential remains untested at proteome scale. Isoleucine was recently eliminated from ribosomal proteins in Escherichia coli , establishing that amino acid alphabet reduction is feasible. Here we ask whether an entire amino acid can be eliminated from a proteome, and develop a computational framework to identify the best target. Using two independent approaches — ProteinMPNN structure-based probabilities and multiple sequence alignment conservation — we define “keep-score” as the fraction of positions where the native residue is optimal. Both methods converge on an unexpected candidate: glutamine has the lowest keep-score, with proline and glycine the highest — counter to substitution-matrix intuition. Glutamine’s low keep-score is not explained by a single obvious substitute; glutamate is preferred in only 14% of replacements. Removing this target proteome-wide, we replaced every glutamine across 4,148 proteins with ProteinMPNN-optimal alternatives and modeled the resulting sequences with AlphaFold2. The recoded proteome maintained native-like structures: 85.5% of models exceeded a TMscore of 0.8, indistinguishable from the 85.9% baseline for rebuilt native sequences. Orthogonal validation — ESMFold predictions, Rosetta energy calculations, and conformational ensemble comparisons — revealed no evidence of systematic misfolding attributable to glutamine removal. As a consistency check, a glutamine-free TEM-1 β-lactamase designed with ProteinMPNN conferred ampicillin resistance in E. coli , indicating fold preservation can extend to biological function. Evolutionary evidence further supports these findings: 24% of E. coli proteins have glutamine-free orthologs in prokaryotic genomes, and glutamine ranks lowest in keep-score in Saccharomyces cerevisiae . These results show that an entire amino acid can be removed from a proteome with folds broadly preserved, establishing keep-score as a general framework and glutamine as the primary candidate for recoding. Crucially, this reflects a computational analysis of structural replaceability, not a demonstration of biological dispensability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departamento de Ingeniería Celular y Biocatálisis, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México.
ORCID-Profile: Alejandro Garciarrubio, Lorenzo Segovia
Förderung
- Secihti,Mexico
Zitieren
APA
Garciarrubio, A., Ramos-Cerrillo, B., Morett, E., & Segovia, L. (2026). Folding without glutamine: Proteome-scale removal of a canonical amino acid. PLOS Computational Biology, 22(11), e1014931. https://doi.org/10.1371/journal.pcbi.1014931
Vancouver
Garciarrubio A, Ramos-Cerrillo B, Morett E, Segovia L. Folding without glutamine: Proteome-scale removal of a canonical amino acid. PLOS Computational Biology. 2026;22(11):e1014931. doi:10.1371/journal.pcbi.1014931
BibTeX
@article{Garciarrubio2026,
author = {Garciarrubio, Alejandro and Ramos-Cerrillo, Blanca and Morett, Enrique and Segovia, Lorenzo},
title = {Folding without glutamine: Proteome-scale removal of a canonical amino acid},
journal = {PLOS Computational Biology},
year = {2026},
volume = {22},
number = {11},
pages = {e1014931},
doi = {10.1371/journal.pcbi.1014931}
}
EUVIMED